Addition of recommendations for the use of recombinant human thrombomodulin to the "Expert consensus for the treatment of disseminated intravascular coagulation in Japan"

Thrombosis Research

Volumn 134, Issue 4, 2014, Pages 924-925

  Wada, H ^a   Okamoto, K ^b   Iba, T ^c   Kushimoto, S ^d   Kawasugi, K ^e   Gando, S ^f   Madoiwa, S ^g   Uchiyama, T ^h   Mayumi, T ⁱ   Seki, Y ^j  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KITAKYUSHU CITY YAHATA HOSPITAL   (Japan)

^c JUNTENDO UNIVERSITY   (Japan)

^d Graduate School of Biomedical Engineering   (Japan)

^e TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g JICHI MEDICAL UNIVERSITY   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION TAKASAKI GENERAL MEDICAL CENTER   (Japan)

ⁱ UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^j Department of Internal Medicine   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; PLACEBO; RECOMBINANT THROMBOMODULIN;

DISSEMINATED INTRAVASCULAR CLOTTING; DRUG MECHANISM; HUMAN; JAPAN; LETTER; POSTMARKETING SURVEILLANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84908201166     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.07.033     Document Type: Letter

References (9)

1. Wada H, Asakura H, Okamoto K, Iba T, Uchiyama T, Kawasugi K, et al. Yoshioka A; Japanese Society of Thrombosis Hemostasis/DIC subcommittee: Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res 2010;125:6-11.
2. Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007;5:31-41.
3. Mimuro J, Takahashi H, Kitajima I, Tsuji H, Eguchi Y, Matsushita T, et al. Impact of recombinant soluble thrombomodulin (thrombomodulin alfa) on disseminated intravascular coagulation. Thromb Res 2013;131:436-43.
4. Vincent JL, Ramesh MK, Ernest D, Larosa SP, Pachl J, Aikawa N, et al. A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular Coagulation. Crit Care Med 2013;41:2069-79.
5. Esmon NL, Owen WG, Esmon CT. Isolation of a membrane-bound cofactor for thrombin- catalyzed activation of protein C. J Biol Chem 1982;257:859-64.
6. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1995;270:14477-84.
7. Suzuki K, Kusumoto H, Deyashiki Y, Nishioka J, Hashimoto S, Maruyama I, et al. Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. EMBO J 1987;6:1891-7.
8. Suzuki K, Hayashi T, Nishioka J, Zushi M, Honda K, Yamamoto S, et al. A domain composed of epidermal growth factor-like structures of human thrombomodulin is essential for thrombin binding and for protein C activation. J Biol Chem 1989;264:4872-6.
9. Aikawa N, Shimazaki S, Yamamoto Y, Saito H, Maruyama I, Ohno R, et al. Aoki N: Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock 2011;35:349-54.